Impulsivity and control of inhibition in Benign Focal Childhood Epilepsy (BFCE)

H Chevalier1, M N Metz-Lutz, S J Segalowitz

  • 1Hospital for Sick Children, Toronto, Ontario, Canada.

Brain and Cognition
|June 17, 2000
PubMed

Insights

Children with benign epilepsy show deficits in action regulation and inhibition, impacting frontal lobe functions. These findings highlight potential cognitive challenges in pediatric epilepsy patients without obvious neurological signs.

Area of Science:

  • Neuroscience
  • Developmental Psychology
  • Pediatric Neurology

Background:

  • Childhood epilepsy involves abnormal brain activity.
  • Frontal lobe development is crucial for cognitive functions like action regulation and inhibition.
  • Benign epilepsy may impact these functions even without overt neurological signs.

Purpose of the Study:

  • To investigate the effects of benign epilepsy on frontal lobe functions in children.
  • To assess action regulation and inhibition in children with benign epilepsy compared to controls.

Main Methods:

  • A cohort of 13 children with benign epilepsy (ages 6-12) was matched with 13 controls.
  • Participants completed tasks assessing impulsivity and inhibitory control: Continuous Performance Test (CPT), Stop Signal Paradigm, Stroop test, and Matching Familiar Figures Test (MFFT).

Main Results:

  • Children with benign epilepsy exhibited significantly more errors on the MFFT (p < .02).
  • They also made more errors under interference conditions on the Stroop test (p < .01).
  • A longer response time to the Stop Signal was observed in the epilepsy group (p < .05), with no differences in nonexecutive functions.

Conclusions:

  • Children with benign epilepsy demonstrate impairments in specific measures of impulsivity and inhibition.
  • These deficits suggest potential underlying frontal lobe dysfunction in pediatric benign epilepsy.
  • Findings underscore the need for targeted cognitive assessments in children with epilepsy.

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...